A new player in the promising
field of immuno-oncology

Globavir’s initial oncology program, BC001, is a novel HIF1 inhibitor for the treatment of solid tumors and has been licensed out to Sorrento Therapeutics.

Following BC001, Globavir is utilizing its data-driven platform to generate a pipeline of small molecules against immuno-oncology targets such as PD-1, IDO and TDO. Our goal is to become a significant player in the most exciting oncology field by proposing a different approach to the traditional drug discovery and business models.